| Abstract |
Objective: To observe the clinical effect of quetiapine in the treatment of bipolar disorder. Methods: From June 2017 to December 2018, 86 patients with bipolar disorder who were admitted to our hospital were randomly divided into 2 groups, 43 cases each. The control group was treated with lithium carbonate combined with quetiapine, and the observation group was treated with quetiapine alone. The changes of BRMS score, clinical effect, quality of life and adverse reactions were compared before and after treatment. RESULTS: There was no significant difference in the BRMS score between the two groups before treatment (P>00.05). The improvement of the observation group at 2w, 4w and 6w after treatment was better than that of the control group. There was a statistical difference between the two groups (P< 0.05). In the treatment efficiency, the control group was 86.05% (37/43), and the observation group was 88.37% (38/43). There was no significant difference between the two groups (P>0.05). In terms of quality of life, there were statistical differences in the scores of physical, social, physiological, and emotional functions between the two groups (P<0.05). In terms of adverse reactions, the incidence of the control group was 18.6% (8/43), and the incidence of the observation group was 4.65% (2/43). There was a statistically significant difference between the two groups (P<0.05). Conclusion: The overall efficacy of lithium carbonate + quetiapine in the treatment of patients with bipolar disorder is comparable to that of quetiapine alone, while the latter has a faster onset of action and fewer adverse reactions, and can significantly improve the quality of life of patients. High security, so it is worth promoting and applying.
|